RxDoctor Payments Data

George Gura, DO

Internal Medicine · Ankeny, IANPI 1194165639

Payments from drug & device makers

$769in general payments, 2019–2025

Across 36 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$203
  • Boehringer Ingelheim$164
  • AbbVie$104
  • Lilly USA, LLC$62
  • Phathom Pharmaceuticals, Inc.$58
  • Medtronic$52
  • plus $125 from 5 others

What the payments were for

  • Food & beverage$75098%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769 in reported general payments places this provider in the 80th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$78,897
Medicare patients
184
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$76,194
EliquisApixaban65$66,048
JardianceEmpagliflozin36$33,852
XareltoRivaroxaban14$19,514
JanuviaSitagliptin Phosphate14$18,181
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$9,151
MyrbetriqMirabegron19$8,562
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,770
Dexlansoprazole DrDexlansoprazole26$5,643
Humalog Kwikpen U-100Insulin Lispro12$5,273
Duloxetine Hcl59$2,384
Gabapentin128$1,660
Atorvastatin Calcium210$1,435
Tamsulosin Hcl72$1,263
Pantoprazole Sodium67$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$203$76,19443 claims
PfizerEliquis$14$66,04865 claims
Boehringer IngelheimJardiance$164$33,85236 claims
Johnson & JohnsonXarelto$17$19,51414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Ankeny

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →